Back to Newsroom

GlobeImmune Engages Cantor Fitzgerald as Financial Advisor to Assist With Evaluation of Strategic Options

LOUISVILLE, CO–(Marketwired – August 13, 2015) – GlobeImmune, Inc. (NASDAQ: GBIM), a biopharmaceutical company focused on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen® platform, announced today that it has engaged Cantor Fitzgerald & Co. as its exclusive financial advisor to assist in evaluating strategic alternatives intended to maximize shareholder value for GlobeImmune’s stockholders.

Click here to read more